AdAlta Pty Ltd (AdAlta) has had its key patent granted by the United States Patent and Trademark Office which protects the development of i-bodies.
The patent, entitled “Binding moieties based on shark IgNAR domains”, provides an exclusivity period until June 2025. The patent specifically covers a method of modifying a number of human proteins called I-set domains to include features of the shark single domain antibody. In addition to this newly granted patent in the US, AdAlta has other granted patents in Australia and patents pending in Europe, Japan and Canada.
i-bodies are a new class of therapeutic proteins that contain the unique structural and functional properties of the single domain shark antibody. AdAlta is focused on developing the i-body based therapeutics against various disease targets exploiting some of the key benefits i-bodies have over conventional antibodies and other antibody fragments.
Sam Cobb, CEO of AdAlta said “The grant of this broad patent for AdAlta underpins our current platform, which we are continuing to develop and this grant in such a commercially important region is an important milestone for us.”
AdAlta is a biotechnology company committed to the discovery, development and commercialization of the i-body platform for therapeutic use. AdAlta aims to provide an alternative approach to drug discovery by candidates from its various libraries for disease conditions.
FOR FURTHER INFORMATION PLEASE CONTACT
CEO and Managing Director
Phone: +61 407 899 867